This sessions introduces the participants to the current situation and definiton of polymedication, including the basic concept of drug therapy as well as patient involvement in managing complex drug therapies and polymedication.Together, we will exploe existing examples of patient-led and patient-initiated research. Aim is to provide related skills and preparedness in a polypharmacy setting.
This session conveys principles of drug-drug-interactions (DDIs) and explores patient perspectives in DDIs with emphasis on patient-reported outcomes.
This session conveys principles of drug-gene-interactions (DDIs) as wells as drug-drug-gene-interactions (DDGIs) and includes basic concepts of genomics. Ethical and legal aspects of research with genetic materials are discussed as well as pharmacogenetics.
This sessions introduces the participants to patient vulnerability factors to increased risk of potential DDI. For example, it includes gender-related and individual differences. The session evolves around basic concepts of equity, diversity and inclusion and related ethical or cultural consideration in drug prescription.
In this session, fundamental concepts in reporting of side effects and adverse as well as serious adverse effects are presented and the use of patient-reported outcome measures (PROMs) is dicussed.
This sessions introduces the participants to digital health tools and gives insights into their benefits, thier applications and the role of safety signal reporting.
This sessions explores the implications of research in polypharmacy from the perspective of law and ethics while particularly considering vulnerable patient groups like children, the elderly and patients with cognitive impairment.